Treatment of delusions in Alzheimer's disease - Response to pharmacotherapy

Dementia and Geriatric Cognitive Disorders

Volumn 22, Issue 3, 2006, Pages 260-266

  Fischer, Corinne ^a,b   Bozanovic, Radenka ^a   Atkins, Jana H ^a   Rourke, Sean B ^a,b  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Alzheimer's disease; Antipsychotics; Delusions; Dementia; Psychosis

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BUSPIRONE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; NEUROLEPTIC AGENT; NEW DRUG; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; XANOMELINE;

ABSENCE OF SIDE EFFECTS; AGITATION; ALZHEIMER DISEASE; CLINICAL TRIAL; DELUSION; DROWSINESS; DRUG EFFICACY; DRUG RESPONSE; DYSKINESIA; EXTRAPYRAMIDAL SYMPTOM; GAIT DISORDER; GASTROINTESTINAL SYMPTOM; HUMAN; MEDICAL LITERATURE; MEDLINE; MOOD DISORDER; PARKINSONISM; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; CHOLINESTERASE INHIBITORS; DELUSIONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; NOOTROPIC AGENTS; RANDOMIZED CONTROLLED TRIALS;

EID: 33748203709     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000094975     Document Type: Review

References (47)

1. Bassiony MM, Steinberg MS, Warren A, Rosenblatt A, Baker AS, Lyketsos CG: Delusions and hallucinations in Alzheimer's disease: prevalence and clinical correlates. Int J Geriatr Psychiatry 2000;15:99-107.
2. Gormley N, Rizwan MR: Prevalence and clinical correlates of psychotic symptoms in Alzheimer's disease. Int J Geriatr Psychiatry 1998;13:410-414.
3. Jeste DV, Wragg RE, Salmon DP, Harris MJ, Thai LJ: Cognitive deficits of patients with Alzheimer's disease with and without delusions. Am J Psychiatry 1992;149:184-189.
4. Migliorelli R, Petracca G, Teson A, Sabe L, Leiguarda R, Starkstein SE: Neuropsychiatric and neuropsychological correlates of delusions in Alzheimer's disease. Psychol Med 1995;25:505-513.
5. Rabins PV, Mace NL, Lucas MJ: The impact of dementia on the family. JAMA 1982;248:333-335.
6. Steele C, Rovner B, Chase GA, Folstein M: Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Am J Psychiatry 1990;147:1049-1051.
7. Haupt M, Kurz A: Predictors of nursing home placement in patients with Alzheimer's disease. Int J Geriatr Psychiatry 1993;8;741-746.
8. Magni E, Binetti G, Bianchetti A, Trabucchi M: Risk of mortality and institutionalization in demented patients with delusions. J Geriatr Psychiatr Neurol 1996;9:123-126.
9. Kane JM: Pharmacological treatment of schizophrenia. Biol Psychiatry 1999;46:1396-1408.
10. Buckley PF: New dimensions in the pharmacologic treatment of schizophrenia and related psychoses. J Clin Pharmacol 1997;37:363-378.
11. Rainer MK, et al: Effect of risperidone on behavioral and psychological symptoms and cognitive function in dementia. J Clin Psychiatry 2001;62:894-900.
12. Jeste DV, Okamoto A, Napolitano J, Kane JM, Martinez RA: Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry 2000;157:1150-1155.
13. Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M: Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry 1999;60:107-115.
14. Shigenobu K, Ikeda M, Fukuhara R, Maki N, Hokoishi K, Nebu A, Komori K, Tanabe H: Reducing the burden of caring for Alzheimer's disease through the amelioration of 'delusions of theft' by drug therapy. Int J Geriatr Psychiatry 2002;17:211-217.
15. Street JS, Clark WS, Kadam DL, Mitan SJ, Juliar BE, Feldman PD, Breier A: Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementia. Int J Geriatr Psychiatry 2001;16(suppl 1):S62-S70.
16. Street JS, Clark WS, Gannon KS, Cummings JL, Bymaster FP, Tamura RN, Mitan SJ, Kadam DL, Sanger TM, Feldman PD, Tollefson GD, Breier A: Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry 2000;57:968-976.
17. Clark WS, Street JS, Feldman PD, Breier A: The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease. J Clin Psychiatry 2001;62:34-40.
18. De Deyn PP, Carrasco MM, Deberdt W, Jeandel C, Hay DP, Feldman PD, Young CA, Lehman DL, Breier A: Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. Int J Geriatr Psychiatry 2004;19:115-126.
19. Scharre DW, Chang SI: Cognitive and behavioral effects of quetiapine in Alzheimer disease patients. Alzheimer Dis Assoc Disord 2002;16:128-130.
20. Fujikawa T, Takahashi T, Kinoshita A, Kajiyama H, Kurata A, Yamashita H, Yamawaki S: Quetiapine treatment for behavioral and psychological symptoms in patients with senile dementia of Alzheimer type. Neuropsychobiology 2004;49:201-204.
21. Thompson S, Lanctot KL, Herrmann N: The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease. Expert Opin Drug Saf 2004;3:425-440.
22. Holmes C, Wilkinson D, Dean C, Vethanayagam S, Olivieri S, Langley A, Pandita-Gunawardena ND, Hogg F, Clare C, Damms J: The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology. 2004;63:214-219.
23. Paleacu D, Mazeh D, Mirecki I, Even M, Barak Y: Donepezil for the treatment of behavioral symptoms in patients with Alzheimer's disease. Clin Neuropharmacol 2002;25:313-317.
24. Barak Y, Bodner E, Zemishlani H, Mirecki I, Aizenberg D: Donepezil for the treatment of behavioral disturbances in Alzheimer's disease: A 6-month open trial. Arch Gerontol Geriatr 2001;33:237-241.
25. Rosier M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stahelin HB, Hartman R, Gharabawi M: Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial. BMJ 1999;318:633-638. Erratum in: BMJ 2001;322:1456.
26. Cummings JL, Schneider L, Tariot PN, Kershaw PR, Yuan W: Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease. Am J Psychiatry 2004;161:532-538.
27. Bodick NC, Offen WW, Shannon HE, Satterwhite J, Lucas R, van Lier R, Paul SM: The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease. Alzheimer Dis Assoc Disord 1997;11(suppl 4):S16-S22.
28. Levy ML, Cummings JL, Fairbanks LA, Bravi D, Calvani M, Carta A: Longitudinal assessment of symptoms of depression, agitation, and psychosis in 181 patients with Alzheimer's disease. Am J Psychiatry 1996;153:1438-1443.
29. Lopez OL, Brenner RP, Becker JT, Ulrich RF, Boller F, DeKosky ST: EEG spectral abnormalities and psychosis as predictors of cognitive and functional decline in probable Alzheimer's disease. Neurology 1997;48:1521-1525.
30. Bylsma FW, Folstein MF, Devanand DP, et al: Delusions and patterns of cognitive impairment in Alzheimer's disease. Neuropsychiatry Neuropsychol Behav Neurol 1994;7:98-103.
31. Rabins PV, Folstein MF: Delirium and dementia: diagnostic criteria and fatality rates. Br J Psychiatry 1982;140:149-153.
32. Steele C, Rovner B, Chase GA, Folstein M: Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Am J Psychiatry 1990;147:1049-1051.
33. Haupt M, Romero B, Kurz A: Delusions and hallucinations in Alzheimer's disease: Results from a two year longitudinal study. Geriatr Psychiatry 1996;11:965-972.
34. Magni E, Binetti G, Bianchetti A, Trabucchi M: Risk of mortality and institutionalization in demented patients with delusions. J Geriatr Psychiatry Neurol 1996;9:123-126.
35. Jeste D Ropacki S: Epidemiology of and risk factors for psychosis of Alzheimer's disease: a review of 55 studies published from 1990 to 2003. Am J Psychiatry 2005;162:2022-2030.
36. Goldsmith SK, Shapiro RM, Joyce JN: Disrupted pattern of D2 dopamine receptors in the temporal lobe in schizophrenia. A post-mortem study. Arch Gen Psychiatry 1997;54:649-658.
37. Paulsen JS, Ready RE, Stout JC, Salmon DP, Thai LJ, Grant I, Jeste DV: Neurobehaviors and psychotic symptoms in Alzheimer's disease. J Int Neuropsychol Soc 2000;6:815-820.
38. Mega MS, Lee L, Dinov ID, Mishkin F, Toga AW, Cummings JL: Cerebral correlates of psychotic symptoms in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2000;69:167-171.
39. Kotrla KJ, Chacko RC, Harper RG, Doody R: Clinical variables associated with psychosis in Alzheimer's disease. Am J Psychiatry 1995;152:1377-1379.
40. Flynn FG, Cummings JL, Gornbein J: Delusions in dementia syndromes: investigation of behavioral and neuropsychological correlates. J Neuropsychiatry Clin Neurosci 1991;3:364-370.
41. Zubenko GS, Moossy J, Martinez AJ, et al: Neuropathologic and neurochemical correlates of psychosis in primary dementia. Arch Neurol 1991;48:619-624.
42. Sweet RA, Nimgaonkar VL, Devlin B, Lopez OL, DeKosky ST: Increased familial risk of the psychotic phenotype of Alzheimer disease. Neurology 2002;58:907-911.
43. Wragg RE, Jeste DV: Overview of depression and psychosis in Alzheimer's disease. Am J Psychiatry 1989;146:577-587.
44. Lyketsos CG, Steinberg M, Tschanz JT, Norton MC, Steffens DC, Breitner JC: Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry 2000;157:708-714.
45. Farber NB, Rubin EH, Newcomer JW, Kinscherf DA, Miller JP, Morris JC, Olney JW, McKeel DW Jr: Increased neocortical neurofibrillary tangle density in subjects with Alzheimer disease and psychosis. Arch Gen Psychiatry 2000;57:1165-1173.
46. Sweet RA, Hamilton RL, Lopez OL, Klunk WE, Wisniewski SR, Kaufer DI, Healy MT, DeKosky ST: Psychotic symptoms in Alzheimer's disease are not associated with more severe neuropathologic features. Int Psychogeriatr 2000;12:547-558.
47. Schneider L, Dagerman K, Insel P: Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005;294:1934-1943.